Yüklüyor......
Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions
Prognosis of diffuse large B-cell lymphoma (DLBCL) has considerably improved during the last decade, mainly due to the addition of rituximab to chemotherapy. However, a significant proportion of patients still experience primary refractory disease or short-term relapses, conferring poor survival. Th...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2013
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3621721/ https://ncbi.nlm.nih.gov/pubmed/23579927 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S42574 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|